Foot Ulcer, Diabetic
Conditions
Keywords
Foot, Ulcer, Diabetes, Amputation, Limb salvage
Brief summary
In this randomized, multi-center, cross-over study, the efficacy and safety of NEOX® CORD 1K will be evaluated in patients suffering from non-healing diabetic foot ulcers. NEOX® CORD 1K is a cryopreserved human Amniotic Membrane and Umbilical Cord (AM/UC) matrix intended for use as a wound covering for dermal ulcers and defects. It is designated as a Human Cell & Tissue Product (HCT/P) by the U.S. FDA.
Detailed description
Patients identified for the study will have a non-healing diabetic ulcer, between 1-25cm² in size. The patient's wound(s) will be monitored for 2 weeks to document the wound pathology. Patients with less than 30% wound area reduction during the 2 week screening period and who meet all of the inclusion and none of the exclusion criteria, will be enrolled in the study. All patients will be assigned to a study or control group and undergo sharp debridement. NEOX® CORD 1K matrix will be applied to the treatment group on the day of debridement, covered with a wound veil, and standard dressing. Both groups will be monitored weekly, and the % decrease in wound size will be recorded at Baseline and Weeks 1, 2, 3, 4, 6, 8 and 12. If the wound is not progressing, additional application of NEOX® CORD 1K may be applied. The time to complete closure will be recorded for both groups. The study duration will be 12 weeks. Subjects in the control group that continue to suffer a non-healing wound at the week 12 visit will be offered an opportunity to cross-over to NEOX treatment and followed for an additional 12 weeks.
Interventions
OTHERNEOX® CORD 1K
Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
PROCEDUREStandard of Care (Pressure Bandage)
Standard of Care wound, pressure dressing applied as needed at each visit.
Sponsors
Amniox Medical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Between 18 years and 80 years of age inclusive 2. Confirmed diagnosis of Type I or Type II Diabetes 3. Males and Females diagnosed with a diabetic foot ulcer that is 1-25cm² 4. At least one foot ulcer that is UT Grade IA 5. Evidence of proper circulation which includes: An Index Ulcer defined as chronic (presence of wound for \> 4 weeks) but not present for more than 52 weeks at the Screening Visit 6. The Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot 7. The Index Ulcer extends into the dermis or subcutaneous tissue with no evidence of exposed muscle, tendon, bone, or joint capsule 8. Wound is free of necrotic debris and clinical signs of infection 9. Patient has adequate circulation to the foot 10. In patients with non-compressible ankle vessels there is adequate flow to the foot.
Exclusion criteria
1. The Index Ulcer is of non-diabetic pathophysiology and/or over an active Charcot deformity 2. The Index Ulcer is UT Grade IB or higher (worsening) 3. Gangrene is present on any part of the affected foot 4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit 5. Patient is currently receiving renal dialysis 6. Patient has a glycated hemoglobin A1c (HbA1c) level of \> 12% 7. Patient has significant renal impairment 8. Chronic oral steroid use \> 7.5 mg daily 9. Requiring intravenous (IV) antibiotics to treat the index wound infection 10. Patient has an ulcer within 15cm of the Index Ulcer identified for study consideration 11. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents 12. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS) 13. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or purulent drainage from the wound site 14. Patient has active malignancy other than non-melanoma skin cancer 15. Patient's Index Ulcer has decreased by ≥ 30% during 2-week screening period 16. Patient has untreated alcohol or substance abuse at the time of screening 17. Pregnant women 18. Patient is currently enrolled or participated in another investigational device, drug, or biologic trial within 60 days of screening 19. Patient has allergy to primary or secondary dressing materials used in this trial 20. Patient has an allergy to amphotericin-B or Dulbecco's Modified Eagle Medium (DMEM) 21. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete wound closure | 12 weeks | Complete closure of the index wound, defined as 100% re-epithelialization as determined by the Investigator |
| Number of participants with adverse events | 12 weeks | Number of participants with adverse events will be compared between the two groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blinded Reader Assessment | 12 weeks and 24 weeks | Percent of wounds achieving complete closure per the assessment of a Blinded Reader (by blinded photograph of wound and measurement acetate). |
| Number of applications | 12 weeks | Number of applications of study product (up to 12 weeks from Baseline) |
| Time to Initial Wound Closure | Up to 12 weeks or 24 weeks (Crossover) | Time to initial wound closure (Up to12 weeks from Baseline or 24 weeks for crossover group) |
Countries
United States
Outcome results
None listed